Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06991114 · ClinicalTrials.gov registry record · Phase 2

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

A Phase 2 study of Scleroderma and Rheumatoid Arthritis (RA), sponsored by Artiva Biotherapeutics.

Recruiting
Registry status
Phase 2
Development phase
90
Enrollment target
20
Study locations

NCT06991114 is a Phase 2 study of Scleroderma and Rheumatoid Arthritis (RA) that is actively recruiting participants, run by Artiva Biotherapeutics. The registered enrollment target is 90 participants, below the 399-participant average among 23 other Scleroderma trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06991114, a Phase 2 study of Scleroderma and Rheumatoid Arthritis (RA), is actively recruiting participants, sponsored by Artiva Biotherapeutics.

RECRUITING
Registry status
Phase 2
Development phase
90 participants
Enrollment target
20
Study locations

Study Summary

A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically modified allogeneic NK cell, in combination with rituximab.

Conditions Studied

Scleroderma Rheumatoid Arthritis (RA) Systemic Sclerosis (SSc) Myositis Sjogren Syndrome IIM Sjogrens Disease Refractory Rheumatoid Arthritis (RA) Idiopathic Inflammatory Myopathies (IIMs)

Interventions

  • DRUG Allogeneic NK Cells

Study Locations (20)

Texas

  • Artiva Investigational Site Arlington - Arlington
  • Artiva Investigational Site Katy - Katy
  • Artiva Investigational Site Mesquite - Mesquite
  • Artiva Investigational Site Woodland - Woodland

Other

  • Artiva Investigational Site Sofia - Sofia
  • Artiva Investigational Site Marseille - Marseille
  • Artiva Investigational Site Montpellier - Montpellier
  • Artiva Investigational Site Toulouse - Toulouse

Florida

  • Artiva Investigational Site Aventura - Aventura
  • Artiva Investigational Site Jupiter - Jupiter
  • Artiva Investigational Site Plantation - Plantation

California

  • Artiva Investigational Site Covina - Covina
  • Artiva Investigational Site Los Alamitos - Los Alamitos

North Carolina

  • Artiva Investigational Site Charlotte - Charlotte
  • Artiva Investigational Site Charlotte - Charlotte

Alabama

  • Artiva Investigational Site Tuscaloosa - Tuscaloosa

Arizona

  • Artiva Investigational Site Phoenix - Phoenix

Illinois

  • Artiva Investigational Site Willowbrook - Willowbrook

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2025-07-09
Est. Completion 2029-01
Phase Phase 2

Sponsor

Artiva Biotherapeutics

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06991114

The ClinicalTrials.gov registry entry for NCT06991114 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 399-participant average among 23 other Scleroderma trials with a reported enrollment target (77% lower). The listed sponsor is Artiva Biotherapeutics, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 9 conditions, with Scleroderma appearing as the primary indexed condition, and to 1 intervention - of which Allogeneic NK Cells is the first listed.

NCT06991114 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Texas, Other, Florida.

Frequently Asked Questions

What is clinical trial NCT06991114 about?

NCT06991114 is a clinical study titled "AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.". A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically modified allogeneic NK cell, in combination with rituximab.

What is the current status of trial NCT06991114?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2025-07-09. Estimated completion is 2029-01.

What conditions does trial NCT06991114 study?

This clinical trial studies the following conditions: Scleroderma, Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Myositis, Sjogren Syndrome.

What interventions are being tested in trial NCT06991114?

The interventions under investigation include: Allogeneic NK Cells (DRUG).

Who is sponsoring clinical trial NCT06991114?

This trial is sponsored by Artiva Biotherapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06991114 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Scleroderma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Scleroderma

All registered trials for this condition

Rheumatoid Arthritis (RA)

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.